Clinical trial
Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers
NCT00233337 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00233337 |
|---|---|
| Title | Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers |
| Official title | Open-label, Multi-center, Non-comparative Efficacy, Safety, and Tolerability Study of Co-artemether in the Treatment of Acute Uncomplicated Malaria in Non-immune Patients |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acute Uncomplicated P. Falciparum Malaria |
| Intervention type | Drug |
| Interventions | Co-artemether |
| Start date | May 1, 2001 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Oct 5, 2005 |
| Last update posted | Apr 27, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: